A phase II, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of alpha-1 antitrypsin (AAT) (glassia®) in the treatment of recent-onset type 1 diabetes
Yael Lebenthal, Avivit Brener, Eli Hershkovitz, Naim Shehadeh, Shlomit Shalitin, Eli C. Lewis, Dana Elias, Alon Haim, Galia Barash, Neta Loewenthal, Nehama Zuckerman-Levin, Michal Stein, Naveh Tov, Marianna Rachmiel
Research output: Contribution to journal › Article › peer-review
12Scopus
citations
Fingerprint
Dive into the research topics of 'A phase II, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of alpha-1 antitrypsin (AAT) (glassia®) in the treatment of recent-onset type 1 diabetes'. Together they form a unique fingerprint.